Search | Clinical Trials Finder

Conditions: Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma, Refractory Neuroblastoma
Interventions: Naxitamab, Irinotecan, Temozolomide, Sargramostim granulocyte-macrophage colony stimulating factor; Drug
Lead sponsor: Steven DuBois, MD; Other
Eligibility: 1 Year to 30 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Neuroblastoma
Interventions: Naxitamab; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: 12 Months to 21 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2036
U.S. locations: 21
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 18 more

Conditions: Recurrent Osteosarcoma
Interventions: humanized anti-GD2 antibody, GM-CSF; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 13 Months to 40 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • New York, New York • Houston, Texas

Conditions: Brain Cancer, Brain Stem Glioma
Interventions: Radioactive iodine-labeled monoclonal antibody omburtamab, External Beam Radiotherapy; Drug · Radiation
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Neuroblastoma
Interventions: GM-CSF + Naxitamab; Biological
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 1 Year and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Indianapolis, Indiana • New York, New York

Conditions: Desmoplastic Small Round Cell Tumor, Peritoneal Cancer, Peritoneal Carcinoma
Interventions: 131 I-omburtamab, WAP-IMRT; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Leptomeningeal Metastasis, Solid Tumor, Adult
Interventions: radiolabeled DPTA-omburtamab; Biological
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more

Conditions: Neuroblastoma, CNS Metastases, Leptomeningeal Metastases
Interventions: 131I-omburtamab; Biological
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: Up to 18 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • Indianapolis, Indiana • New York, New York + 2 more

Conditions: Neuroblastoma
Interventions: Humanized 3F8 Monoclonal Antibody (Hu3F8); Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 2 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Central Nervous System/Leptomeningeal Neoplasms
Interventions: 131I-omburtamab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroblastoma
Interventions: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH, oral β-glucan; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroblastoma
Interventions: Hu3F8 With GM-CSF; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
Interventions: 25 mCi 177Lu- DTPA-omburtamab; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 3 Years to 22 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers
Interventions: Humanized 3F8 Bispecific Antibody, Blood draw; Biological · Other
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions: Iodine I 131 MOAB 8H9; Drug
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: Not listed
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroblastoma, High-Risk
Interventions: cyclophosphamide, NK cells, hu3F8, rIL-2; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroblastoma
Interventions: Hu3F8, GM-CSF, Isotretinoin; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Triple-Negative Breast Cancer
Interventions: Sacituzumab govitecan, Naxitamab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peritoneal Cancer
Interventions: 131 I-8H9; Biological
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 1 Year and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-hodgkin Lymphoma
Interventions: CD38-SADA:177Lu-DOTA Complex; Drug
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Duarte, California • Grand Rapids, Michigan + 3 more

Conditions: Melanoma, Neuroblastoma, Sarcoma
Interventions: 124I-Humanized 3F8; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 3 Years to 90 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions: Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 21 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • New York, New York • Cincinnati, Ohio

Conditions: Medulloblastoma, Childhood
Interventions: 177Lu-DTPA-omburtamab; Drug
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 3 Years to 19 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Rochester, Minnesota • New York, New York • Portland, Oregon + 1 more

Conditions: SCLC, Malignant Melanoma, Sarcoma, High Risk Neuroblastoma
Interventions: GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi), GD2-SADA (1 mg/kg) 177Lu-DOTA (200 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (200 mCi), GD2-SADA (1 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (1 mg/kg) 177Lu-DOTA (100 mCi); Drug
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 16 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Scottsdale, Arizona • Duarte, California • Chicago, Illinois + 5 more

Search by objective public record fields.

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2